伴病理性乳头溢液的乳腺癌患者癌组织整合素β1的表达及意义

doi:10.3969/j.issn.1004-616x.2019.05.006

Abstract

Abstract: OBJECTIVE:Expression of β1 integrin in breast cancer patients with pathological nipple discharge was investigated and its effect on prognosis of patients was evaluated. METHODS:From January 1st,2006 to December 31,2013,112 breast cancer patients with pathological nipple discharge in the People's Hospital of Gansu Province were brought into the study. Another 112 breast cancer patients with breast lumps which were detected by physical examination or not were selected as a control. Immuno-histochemistry was used to detect the difference in expression of β1 integrin and Her-2 in cancer tissues. Survival analysis was used to study the effect of β1 integrin on prognosis of the patients. RESULTS:Among patients with pathological nipple discharge,14.29% (16/112) showed positive expression of β1 integrin which was significantly lower than that in the control group (25%) (χ²=4.073,P=0.044). Survival analyses show that the control group had significantly lower survival than that of the pathological nipple discharge group (HR=1.773,P=0.012). The overall survival with higher expression of β1 integrin was significantly lower than that of lower expression in the nipple discharge group (HR=2.573,P=0.023). The expression of β1 integrin and Her-2 had a positive correlation in the nipple discharge group (r=0.281,P=0.001),Cox proportional hazards model test found that histological-grade,lymph node metastasis,and high expression of β1 integrin were three independent risk factors affecting the overall survival of patients with pathological nipple discharge (P < 0.01). CONCLUSION:High expression of β1 integrin in breast cancer tissues significantly reduced the overall survival of breast cancer patients. Furthermore,breast cancer patients with integrin had lower overall survival,High expression of β1 integrin was positively correlated with poorer prognosis among breast cancer patients with pathological nipple discharge and was positively related to worse pathologic features of breast cancer.

Key words: β1 integrin, breast cancer, pathological nipple discharge, prognostic analysis

CLC Number:

R737.9

SUN Quanwu, DU Xiaoping, HAO Jie, SHI Rong, LIU Bo, HUANG Haiyun. β1 integrin expression in breast cancer patients with pathological nipple discharge[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 368-372.

References

[1] GUI G, AGUSTI A, TWELVES D, et al. INTEND Ⅱ randomized clinical trial of intraoperative duct endoscopy in pathological nipple discharge[J]. Br J Surg, 2018, 105(12):1583-1590.
[2] PARK C J, KIM E K, MOON H J, et al. Reliability of breast ultrasound BI-RADS final assessment in mammographically negative patients with nipple discharge and radiologic predictors of malignancy[J]. J Breast Cancer, 2016, 19(3):308-315.
[3] CHEN L, ZHOU W B, ZHAO Y, et al. Bloody nipple discharge is a predictor of breast cancer risk:a meta-analysis[J]. Breast Cancer Res Treat, 2012, 132(1):9-14.
[4] 吕凤, 张艺骞, 郭晓静, 等. 乳腺浸润性微乳头状癌组织整合素β1和Kindlin-2表达的研究[J]. 中华肿瘤防治杂志, 2015, 22(12):929-935.
[5] SUN Q W, ZHOU C, MA R F, et al. Prognostic value of increased integrin-beta 1 expression in solid cancers:a meta-analysis[J]. Onco Targets Ther, 2018, 11:1787-1799.
[6] HAGA S, IMAI S, MORIMOTO J, et al. Hormone-dependent human tumors express the fms gene-product[J]. Int J Oncol, 1994, 5(4):769-773.
[7] WOLFF A C, HAMMOND M E, SCHWARTZ J N, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. J Clin Oncol, 2007, 25(1):118-145.
[8] YAO E S, ZHANG H, CHEN Y Y, et al. Increased beta1 integrin is associated with decreased survival in invasive breast cancer[J]. Cancer Res, 2007, 67(2):659-664.
[9] NAM K, SON S H, OH S, et al. Binding of galectin-1 to integrin beta1 potentiates drug resistance by promoting survivin expression in breast cancer cells[J]. Oncotarget, 2017, 8(22):35804-35823.
[10] HANKER A B, ESTRADA M V, BIANCHINI G, et al.Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer[J]. Cancer Res, 2017, 77(12):3280-3292.
[11] LESNIAK D, XU Y, DESCHENES J, et al. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer[J]. Cancer Res, 2009, 69(22):8620-8628.
[12] AOUDJIT F, VUORI K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells[J]. Oncogene, 2001, 20(36):4995-5004.
[13] CORDES N, SEIDLER J, DURZOK R, et al. Beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury[J]. Oncogene, 2006, 25(9):1378-1390.
[14] ISHIZUKA Y, KOSHINAGA T, HIRANO T, et al. NRP1 knockdown promotes the migration and invasion of human neuroblastoma-derived SK-N-AS cells via the activation of β1 integrin expression. Int J Oncol, 2018, 53(1):159-166
[15] PAN B, GUO J, LIAO Q, et al. beta1 and beta3 integrins in breast, prostate and pancreatic cancer:A novel implication[J]. Oncol Lett, 2018, 15(4):5412-5416.
[16] LEE T H, SENG S, LI H, et al. Integrin regulation by vascular endothelial growth factor in human brain microvascular endothelial cells:role of alpha6beta1 integrin in angiogenesis[J]. J Biol Chem, 2006, 281(52):40450-40460.
[17] CAMPBELL M R, ZHANG H, ZIAEE S, et al. Effective treatment of HER2-amplified breast cancer by targeting HER3 and beta1 integrin[J]. Breast Cancer Res Treat, 2016, 155(3):431-440.
[18] MARTINELLO R, BECCO P, VICI P, et al. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity[J]. Breast J, 2019, 25(3):444-449.

β1 integrin expression in breast cancer patients with pathological nipple discharge

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[2]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[3]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[4]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[5]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[6]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[7]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[8]	CHEN Mianling, MA Shuoyi. Regulation of migration and invasion of triple-negative breast cancer cell MDA-MB-231 by miR-21 via targeting PDCD4 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 292-297.
[9]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[10]	WANG Lan, ZHANG Yongdong, GUO Hongyun, WANG Tao, WANG Haitao, GUO Huan, YANG Suisheng, LI Xiaoqin, SU Haixiang. Relationships between XRCC3 polymorphisms and breast cancer in northern Chinese women [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 392-396,400.
[11]	DU Juan, HU Xiangyang, LIU Dan, HU Wei, CHEN Tao. Inhibitory effect of total alkaloids of Tougucao on bone metastasis of breast cancer cells in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 435-441.
[12]	XIAO Hongmei, PAN Tianqi, DONG Shunan, FU Lingmeng, WANG Shaokang, SUN Guiju. Menopausal status on risk for breast cancer from tea consumption: a meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 395-399.
[13]	JIANG Pengtao, HU Zhifang, GAO Xingchun, GUO Na, ZHANG Dian, JIANG Fengliang. Involvement of p53 in regulation of DNA damage-induced cell death in MDA-MB-231 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 349-353.
[14]	YANG Shaoyi, ZHANG Qingying, WU Jundong, LIN Qiuqiang, WANG Ruifeng, ZHENG Qingyuan, CAI Fen. Genetic variations in the mitotic checkpoint gene MAD1L1, and risk for breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 209-213.
[15]	ZUO Ran, REN Xiaohu, WU Desheng, LI Ping, WU Wen, XIE Ni, YUAN Jianhui, RANG Weiqing. Bioinformation analysis of data regarding breast cancer prognosis in European and American populations [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(2): 103-108.